Site icon pharmaceutical daily

Global $70 Billion Regenerative Medicine Market Analysis to 2028 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Regenerative Medicine Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Product Type, Material, Application, and Region” report has been added to ResearchAndMarkets.com’s offering.

The Global Regenerative Medicine Market – which grew from approximately US$ 15 billion in 2017 to approximately US$ 30 billion in 2022 – is forecasted to grow further into approximately US$ 70 billion opportunities by 2028, owing to the growing severe diseases, infections, and cancers. Rising clinical trials and research & development spending on new advanced healthcare processes and facilities by players and governments are also driving the growth of the market.

Regenerative medicine market is driven by surging trauma cases, genetic disorders, chronic diseases, and other infectious viruses. According to World Health Organization, a specialized international public health organization, stated that nearly 10 million deaths in 2020 are caused by cancer worldwide, the most common cases of cancer were lung, prostate, skin, stomach, colon, and rectum.

Cancer immunotherapy activates, replaces, and regenerates the immune system in order to fight cancer. Cancer immunotherapy is a form of regenerative medicine. The rising number of cancer patients worldwide is driving the growth of the regenerative medicine market.

Patients suffering from wound injuries, serious disorders, and others require cell and gene therapies, representing advanced technology. The high cost of cell and gene therapies is hampering the growth of the market. In 2017, the Food and Drug Administration (FDA), a federal agency of the department of health and human services, approved Luxturna to treat a rare form of inherited blindness that affects 100 to 2000 people in the USA. This treatment cost US$ 425,000 per eye.

COVID-19 has accelerated the growth of the regenerative medicine market. In May 2020, the Global Institute of Stem Cell Therapy and Research (GIOSTAR), received FDA approval for COVID-19 clinical trials with stem cells to treat the COVID-19 patients. In May 2020, According to United Arab Emirates Ministry of Foreign Affairs & International Corporation, stated that a patent has been granted by the Ministry of Economics for the development of an innovative and promising treatment for Covid19 infection using stem cells.

Competitive Landscape:

The global Regenerative Medicine market is highly competitive with ~200 players which include globally diversified players, and regional players as well as a significant number of country-niche players having their niche in regenerative medicine testing and surgeries for severe diseases, infections, and wounds

Regional players held the largest market share by type. While large global players control about 20% of the market share by type. Some of the major players in the market include Integra Lifesciences, Amgen, AstraZeneca, Tissue Regenix, Takeda Pharmaceutical Company Limited, Bayer AG, Novartis AG, Smith+Nephew, Vericel, GSK plc., and others

Conclusion

The global Regenerative Medicine market witnessed significant growth during the period 2017-2021, owing to the rising number of cancer patients worldwide, and continuous upgradation in the technology. The growth rate is expected to remain significant during the forecast period.

Though the market is significantly competitive with ~200 participants, the majority of regional players dominate the market share by type, and global players also hold a significant share.

Key Topics Covered in the Report

A selection of companies mentioned in this report includes

Scope of the Report

Time Period Captured in the Report

By Product Type

By Material

By Application

By Geography

For more information about this report visit https://www.researchandmarkets.com/r/om3kve

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version